Immunoscintigraphy is a tumour imaging technique that can have specificity, but high background radioactivity makes it difficult to obtain tumour imaging soon after the injection of radioconjugate. The aim of this study is to see whether clear tumour images can be obtained soon after injection of a radiolabelled reagent using a new linker with antibody fragments (Fab), in conditions of induced hypertension in mice. Fab fragments of a murine monoclonal antibody against human osteosarcoma were labelled with radioiodinated 3′-iodohippuryl N-ε-maleoyl-L-lysine (HML) and were injected intravenously to tumour-bearing mice. Angiotensin II was administered for 4 h before and for 1 h after the injection of radiolabelled Fab. Kidney uptake of 125 I-labelled-HML-Fab was much lower than that of 125 I-labelled-Fab radioiodinated by the chloramine-T method, and the radioactivity of tumour was increased approximately two-fold by angiotensin II treatment at 3 h after injection, indicating high tumour-to-normal tissue ratios. A clear tumour image was obtained with 131 I-labelled-HML-Fab at 3 h post-injection. The use of HML as a radiolabelling reagent, combined with angiotensin II treatment, efficiently improved tumour targeting and enabled the imaging of tumours. These results suggest the feasibility of PET scan using antibody fragment labelled with 18 F-fluorine substitute for radioiodine.
Immunoscintigraphy using a monoclonal antibody is a technique that makes it possible to get a specific image of a tumour (Corbisiero et al, 1991; Collier et al, 1992; Gasparini et al, 1994) . However, delays caused by slow clearance of radioactivity from normal organs prevent it from obtaining images soon after the administration of radiolabelled reagent. Use of antibody fragments (Fab) accelerates blood clearance of the radiolabel, but the renal uptake of radiolabelled fragments is higher than that of intact antibodies and the absolute amount accumulated in tumours is relatively low.
Recently, we developed a new metabolizable linker, designated HML, designed so that radioiodinated HML-protein conjugate is metabolized and rapidly cleared from the body (Wakisaka et al, 1997) . The radioiodinated HML-protein conjugate is stable in the serum but is rapidly metabolized in the liver to release m-iodohippuric acid, which is cleared through the kidneys.
Vasoactive agents, such as angiotensin II, by producing vasoconstriction in normal tissue, are known to divert arterial blood selectively toward tumours and thereby enhance the delivery of drug-loaded particles (Suzuki et al, 1981; Hori et al, 1985; Hori et al, 1993) . Vasoactive agents have already been used clinically to obtain high accumulations of systemically administered chemotherapeutic drugs to malignant tumours, such as gastric carcinoma (Sato et al, 1995) . By combining the use of antibody fragments radioiodinated with HML and angiotensin II treatment, it may be possible to obtain high tumour uptake of radiolabelled antibody with low background radioactivity sooner, which would make it possible to obtain a clear image of the tumour soon after administration of radiolabelled reagent. In the present study, we investigated the effect of HML-radioiodination and angiotensin II treatment on tumour uptake of radiolabelled antibody fragment in tumour-bearing mice, and whether clear tumour images could be obtained soon after administration of radiolabelled antibody fragment.
MATERIALS AND METHODS

Experimental tumour
KT005 human osteosarcoma cells (Sakahara et al, 1987) were grown in RPMI 1640 (Nissui, Tokyo, Japan) containing 10% fetal calf serum (GI Laboratories, Grand Island, NY, USA) and 0.03% L-glutamine at 37°C in 5% CO 2 . Subconfluent cells were removed from the culture dishes using calcium-and magnesium-free phosphate-buffered saline (PBS) containing 0.02% EDTA to preserve antigenicity, and 5 × 10 6 KT005 cells were inoculated subcutaneously into female Balb/c nu/nu mice. Tumours grew to approximately 800 mg 3 weeks after the inoculation. The tumours were maintained by serial passage of subcutaneous tumour in the nude mice.
Monoclonal antibodies and preparation of Fab fragments
The OST7 antibody (IgG 1 isotype) was raised using human osteogenic sarcoma (Hosoi et al, 1982) , and it has been shown to react with human osteogenic sarcoma cells with an alkaline phosphatase-related substance as an antigen (Tanaka et al, 1986; Nakamura et al, 1987) . OST7 antibody was purified from the ascites of hybridoma-bearing mice using Protein A column chromatography (Bio-Rad, Richmond, CA, USA). Monoclonal antibody 56C (IgG 1 ), which recognizes human chorionic A novel immunoscintigraphy technique using metabolizable linker with angiotensin II treatment gonadotropin, was used as the isotype-matched control antibody . Fab fragments were generated by papain digestion of the whole IgG of OST7 and 56C. Papain was added to IgG in 0.075 M phosphate buffered saline, pH 7.0, to yield an enzyme-IgG weight ratio of 1:33. After incubation at 37°C for 1 h, the reaction was stopped by adding 10% volume of 0.5 M iodoacetamide. The Fab fragments were separated by Superdex 200 column chromatography (Pharmacia Biotech, Uppsala, Sweden) and were further purified from contaminated Fc fragments by Protein A affinity chromatography (Bio-Rad, Richmond, CA, USA).
Radioiodination of Fab
Radioiodination of Fab fragments was done by a two-step procedure (Arano et al, 1994; Wakisaka et al, 1997) . First, HML was radioiodinated, and the radioiodinated HML was then conjugated to the Fab fragment. HML was dissolved in methanol containing 1% acetic acid (0.64 mg ml -1 ), and 32.6 µl of this solution was mixed with 4 µl (14.8 MBq; 400 µCi) of Na[ 125 I] (DuPont, Wilmington, DE, USA). After addition of 8.88 µl of N-chlorosuccinimide (NCS) in methanol (0.5 mg ml -1 ), the reaction mixture was incubated at room temperature for 25 min. Aqueous sodium bisulphite (4.44 µl, 0.72 mg ml -1 ) was then added to quench the reaction. The radiochemical yield of [ 125 I]-HML was determined by TLC developed with a mixture of chloroform-methanol-acetic acid (40:5:2). Methanol was removed by an N 2 flow prior to subsequent conjugation reaction with Fab.
Before conjugation with [ 125 I]-HML, Fab was treated with 2-iminothiolan (IT), as previously reported (Arano et al, 1994) . Briefly, 14.4 µl of freshly prepared 2-IT (1.0 mg ml -1 ) in welldegassed 0.1 M borate buffer (BB; pH 8.0) containing 2 mM EDTA was added to 250 µl of Fab (2 mg ml -1 ) in the same buffer. After gentle stirring at room temperature for 1 h, excess 2-IT was removed by the centrifuged column procedure (Meares et al, 1984) using a Sephadex G-50 gel (Pharmacia Biotech, Uppsala, Sweden) equilibrated with well-degassed 0.1 M PB (pH 6.0) containing 2 mM EDTA. The filtrate solution (200 µl) was then added to the reaction vial containing 12.6 MBq of crude [ 125 I]-HML. After gentle agitation of the reaction mixture for 1.5 h at room temperature, 29.6 µl of iodoacetamide (10 mg ml -1 ) in 0.1 M PB (pH 6.0) was added into the mixture and incubated for 30 min. Then radiolabelled Fab was purified by the centrifuged column procedure using a Sephadex G-50 gel equilibrated with 0.1 M PB (pH 7.4). The specific activities of the 125 I-HML-IT-Fab (OST7) and 125 I-HML-IT-Fab (56C) were about 0.7 MBq mg -1 and 0.5 MBq mg -1 , respectively. Fab fragments were also radioiodinated by the chloramine-T method (Hunter et al, 1962; Greenwood et al, 1963) . Purified Fab (50 µg) of OST7 in 0.3 M phosphate buffer (pH 7.5) and 125 I (11.1 MBq) were mixed with 2.5 µg of chloramine-T (Nakarai Tesq, Kyoto, Japan) dissolved in 0.3 M phosphate buffer. After reacting for 5 min, the radiolabelled Fab was separated from free iodine by PD-10 gel chromatography (Pharmacia, Uppsala, Sweden). The specific activity of the 125 I-labelled-Fab was about 60.8 MBq mg -1 .
Cell binding assay
The 125 I-labelled-HML-IT-Fab (OST7), 125 I-labelled-Fab (OST7) and 125 I-labelled-HML-IT-Fab (56C) (3-5 ng per 100 µl) were incubated with increasing concentrations of KT005 cells (2 × 10 5 -5 × 10 6 per 100 µl) in 5.7 × 46 mm microcentrifuge tubes for 1 h at 4°C. After centrifugation at 10 000 g, the supernatant was aspirated and the tubes were cut. Then the radioactivity bound to the cells was counted in an auto-well gamma counter. Specific binding to the cells was calculated by subtracting the nonspecific binding of 125 I-labelled-HML-IT-Fab (56C) from the binding of 125 I-labelled-HML-IT-Fab (OST7) and 125 I-labelled-Fab (OST7). The binding of 56C to OST7 was less than 3% of the added radioactivity. The immunoreactive fraction of the radiolabelled antibodies was determined by the method described by Lindmo et al (1984) .
Biodistribution studies
Biodistribution studies were performed when the tumours grew to be about 200 mg in weight. Following a report by Kinuya et al (1996a) , micro-osmotic pumps (Altzet model 1003D, Alza, Palo Alto, CA, USA) filled with 1.2 mg ml -1 of [Asn -1 ,Val 5 ]-angiotensin II (Sigma, St. Louis, MO, USA) dissolved in saline were implanted between scapulae of nude mice bearing KT005 xenografts, 4 h before the injection of radiolabelled HML-Fab. Saline was filled in pumps for the control animals. The pumps infused solution at a constant flow rate of 1.0 µl h -1 for 72 h under physiological conditions at 37°C. At 1, 3 and 24 h after the administration of antibody, the mice were killed, and their organs were removed, weighed and counted for radioactivity. The microosmotic pumps were removed 1 h after the injection of the antibody. As a control study, a fragment of 56C antibody, and for another group, Fab fragment of OST7 radioiodinated by chloramine-T method, were injected with the angiotensin II treatment, and biodistribution was studied at 3 h after the injection. The experimental protocol is shown in Table 1 . Data were expressed as percentage of injected dose per gram of tissue, normalized to 20 g mice, and also as tumour-to-normal tissue ratios.
Immunoscintigraphy
For the imaging of tumour-bearing nude mice, HML was radioiodinated with Na[ 131 I], and subsequent conjugation with Fab fragment of OST7 was performed by procedures similar to those used for 125 I-labelled-HML-IT-Fab (OST7). The specific activity of the 131 I-labelled-HML-IT-Fab (OST7) was about 38.2 MBq mg -1 . As shown in Table 1 , after treatment with angiotensin II, 7.7 MBq of 131 I-labelled-HML-IT-Fab (OST7) was administered intravenously via the tail vein. At 3 h after injection of radiolabelled Fab, mice were anaesthetized by intraperitoneal injection of sodium pentobarbital, and scintigrams were obtained using a gamma camera equipped with a pinhole collimator (Hnatowich et al, 1987; Sakahara et al, 1993) . Table 2 . In addition, Figure 2 shows tumour-to-normal tissue ratios at 3 h after the injection of these radiolabelled fragments. The percentage of injected dose per gram of tissue (%ID g -1 ) of tumours at 1, 3 and 24 h with and without angiotensin treatment after injection of 125 I-labelled-HML-IT-Fab (OST7) were 15.5% and 15.7%, 16.3% and 9.0%, and 3.4% and 3.1%, respectively, and a significant difference in tumour uptake was observed between tumours with and without angiotensin treatment at 3 h after the injection (P < 0.01). The %ID g -1 in blood and kidneys at 3 h after the injection were 5.1% and 5.3%, 2.5% and 3.0%, respectively. The %ID g -1 in blood and kidneys at 3 h of 125 Ilabelled-HML-IT-Fab (OST7) labelled by chloramine-T method were 4.2% and 11.5%, respectively, the latter being significantly higher than that of 125 I-labelled-HML-IT-Fab (OST7). The nonspecific accumulation of control antibody 56C to the tumour was low at 3 h. High tumour-to-normal tissue ratios ranging from 3.2 (blood) to 35.1 (muscle) were obtained using HML with angiotensin treatment.
The scintigraphic images were consistent with the results of biodistribution data (Figure 3) . A clear tumour image with low background activity, including kidneys, was obtained as early as 3 h after injection of 131 I-labelled-HML-IT-Fab (OST7).
DISCUSSION
Immunoscintigraphy and radioimmunotherapy using monoclonal antibody have been used for the detection and treatment of malignant tumours. However, delays caused by slow clearance of unbound antibody from normal tissue and from blood is a problem for both diagnostic and therapeutic applications. Multi-step tumour targeting using a high-affinity binding system such as (strept)avidin-biotin (10 15 M -1 ) is an efficient method of overcoming some of the problems in tumour targeting. In this approach, a lower molecular weight ligand can be used as a carrier of radioisotope for the last step to give higher tumour-to-normal organ ratios sooner, using the rapid clearance of unbound radiolabelled ligand. Some encouraging results have been reported in experimental and clinical studies (Hnatowich et al, 1987; Kalofonos et al, 1990; Paganelli et al, 1991; Saga et al, 1994; Magnani et al, 1996) . We also reported an avidin chase method to facilitate the clearance of unbound radiolabelled biotinylated antibody from the circulation (Kobayashi et al, 1994; Yao et al, 1995) . However, these methods require multiple injections, which can be troublesome. Moreover, they can cause the problem of creating a human anti-streptavidin or anti-avidin antibody, as well as human anti-mouse monoclonal antibodies. Another approach to obtain high tumour-to-background ratios soon after the injection of radiolabelled reagent is the use of fragments, such as Fab and F(ab′) 2 , or single-chain Fv (scFv) as a carrier of radionuclide. Fab and F(ab′) 2 obtained by enzymatic digestion of immunoglobulins demonstrate more rapid tumour targeting, better penetration, and faster blood clearance than their intact IgG molecules. Also, the absence of an Fc region and short residence in the circulation contribute to lower immunogenicity of antibody fragments in vivo. However, fragments have the disadvantage of high kidney uptake and lower absolute uptake in the tumour than intact IgG (Yokota et al, 1993) . Genetically engineered scFv demonstrates much faster clearance from the circulation than Fab and its tumour uptake is very low (Hu et al, 1996) , although dimer forms of scFv can increase absolute tumour uptake. In the present study, we used Fab fragment that has an intermediate character between IgG and scFv, obtained the results of increased absolute uptake by angiotensin II treatment, and decreased renal accumulation of radioactivity by a new conjugation technique. These methods could be used for scFv or other antigen-binding small proteins as well as Fab fragments. Figure 4 schematically illustrates the origin of tumour vasculature from the preexisting vascular bed. Vessel segments are ordered according to Strahler's nomenclature (Strahler et al, 1957) . Tumour neovasculature starts from the junction between a3 and a2, and goes on to feed the growing tumour (Hori et al, 1990; Hori et al, 1993) . Angiotensin II selectively increases the Mean ± SD of % ID g -1 and its tumour-to-blood or tumour-to-kidney ratio for 4-8 mice; *P < 0.01 compared with group C; **P < 0.05 compared with group C resistance of a2 vessels and induces hypertension. Since angiotensin II does not affect the resistance of a3, tumour vasculature originating from the terminal portion of a3 is not affected. Angiotensin II treatment, therefore, selectively redistributes the blood flow to the tumour vascular bed, and it has already been used clinically for induced hypertension chemotherapy. This method can also be applied in antibody-based tumour targeting, and Kinuya et al (1996a) reported high tumour accumulation of radiolabelled IgG in mice. We speculated that in induced hypertension, the increase in tumour accumulation would be higher using Fab fragments than intact IgGs due to their smaller molecular size. Indeed, in our study with Fab fragment, HML-Fab conjugate was highly accumulated in the tumour. HML is a new linker, which was designed to be metabolized in the liver into the m-iodohippuric acid and excreted rapidly through the kidneys. In vitro studies showed that HML-protein conjugates were very stable in serum (Wakisaka et al, 1997) . The binding affinity of the 125 I-labelled-HML-IT-Fab ( 125 I-HML-Fab) to the tumour cells was the same as 125 I-labelled-Fab labelled by chloramin-T method ( 125 I-CT-Fab), but the in vivo studies showed that, at 3 h after the injection of radioiodinated Fab with angiotensin II pretreatment, %ID g -1 of tumour in 125 I-HML-Fab was significantly higher than that of 125 I-CT-Fab, and %ID g -1 in kidneys using 125 I-HML-Fab was significantly lower than that of 125 I-CT-Fab, resulting in a markedly higher tumour-to-kidney ratio using 125 I-HML-Fab. The kidney uptake of 125 I-CT-Fab without angiotensin treatment at 1 h and 24 h were 69.03% and 0.42% (data not shown), respectively. The difference of the radioactivity in the kidneys between 125 I-CT-Fab and 125 I-HMLFab resulted from clearance of radioiodine shortly after injection. Consequently, the combination of angiotensin II pretreatment and HML-radioiodination method made it possible to get high tumour uptake with low background radioactivity including the kidney, and also, this enables clear tumour imaging soon after injection of radiolabelled Fab fragment.
Although the micro-osmotic pump filled with angiotensin was removed at 1 h after injection of radioiodinated Fab, there was no significant difference between the accumulation of tumour with and without angiotensin treatment at 1 h, and it was not until 3 h after the administration that we recognized the difference between the groups with and without angiotensin treatment. Kinuya et al reported that the increase of tumour blood flow and blood volume were observed just 10 min after the administration of angiotensin II by 201 TI and 99m Tc-HSA, and the effect of induced hypertension was confirmed to disappear after the removal of the pump filled with angiotensin II (Kinuya et al, 1996b; . Therefore, although the exact reason remains unknown, there might be some secondary changes after induced hypertension by angiotensin II that enhance tumour uptake of radiolabelled antibody even after normalization of blood pressure. The uptake of 125 I-HML-Fab to the tumour (16.3%) was significantly higher than that of 125 I-CTFab (9.3%) (P < 0.01). A reason for this difference may be the increased stability of 125 I-HML-Fab, since 125 I-CT-Fab seemed to be dehalogenated at the tumour site, and free iodine accumulated in the stomach. In addition, there was no statistically significant difference between tumour accumulations of 125 I-CT-Fab with and without angiotensin treatment at 3 h. This may also be due to the instability of 125 I-CT-Fab compared to 125 I-HML-Fab.
Positron emission tomography (PET) has several advantages over conventional scintigraphy, including better spatial resolution and accurate quantification of tissue uptake. Positron emitter halogens, iodine-124 ( 124 I) and fluorine-18 ( 18 F) might be used for radiolabelling of HML as well as iodine-131. Especially, 18 F is a widely used positron emitter. There have been some reports describing monoclonal antibodies labelled with 18 F (Garg et al, 1992; Vaidyanathan G et al, 1992) . According to these reports, tumour-to-normal tissue ratios were not high within a few hours of administration. Therefore, a new conjugate of 18 F-HML-Fab would be more appropriate for PET imaging.
In conclusion, the combined use of a novel metabolizable linker, HML, for radioiodination of Fab, and angiotensin II treatment, demonstrated high accumulation of Fab in the tumour with low background radioactivity, including the kidney, soon after the injection of radiolabel, resulting in successful tumour imaging, which we named pharmacoimmunoscintigraphy. These results suggest that PET scanning using 18 F-labelled-HML-antibody fragment conjugates would be feasible with this technique.
